Data For Gilead’s Rising Hep C Star Sofosbuvir Support Initial Filing
This article was originally published in The Pink Sheet Daily
Gilead released Phase III data Feb. 4 strong enough to support U.S. and European filing for sofosbuvir, the nucleoside it plans eventually to make the foundation of a fixed-dose pill available by 2015.
You may also be interested in...
Hepatitis C has been the focus of some of biopharma’s most expensive deals the past couple years. In the wake of the licensing, IPO, and M&A frenzy, not many new start-ups have emerged, but there are a still a few niches to fill if entrepreneurs can find funding.
Much of the hep C wish list was on display at the American Association for the Study of Liver Disease meeting in Boston Nov. 10-13 – all-oral interferon-free drug combinations for hepatitis C, regimens that don’t require ribavirin, and the possibility of a one-pill, once-a-day cure – demonstrating the Gold Rush mentality in the hep C space as drug makers race to put the pieces together and grab a share of a burgeoning market.
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.